Paper 34 - A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED OSTEOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Author(s)

• 

  Shantanu Banerji, MD, FRCPC (he/him/his)

  Medical Oncologist
  CancerCare Manitoba
  Winnipeg, Manitoba, Canada

  Slides

Co-Author(s)

• 

  Abha Gupta, MD MSc

  Staff Oncologist
  Princess Margaret Cancer Center
  Toronto, Ontario, Canada
• AA

  Albiruni Ryan Abdul Razak, MB BCh, BM BCh

  Princess Margaret Cancer Center
  Toronto, Ontario, Canada
• 

  Thierry Alcindor, MD

  Harvard University,, Dana-Farber Cancer Center
  Boston, Massachusetts, United States
• QC

  Quincy Chu, MD

  Cross Cancer Institute
  Edmonton, Alberta, Canada
• 

  Karen A. Gelmon, MD (she/her/hers)

  Professor of Medicine, Medical Oncologist
  BC Cancer
  Vancouver, British Columbia, Canada
• GN

  Garth Nicholas, MD

  Medical Oncologist
  Ottawa Hospital Research Institute
  Ottawa, Ontario, Canada
• EW

  Eric Winquist, MD (he/him/his)

  Professor
  Western University
  London, Ontario, Canada
• KH

  Kamal Haider, MD

  Saskatoon Cancer Centre
  Saskatoon, Saskatchewan, Canada
• 

  Torsten O. Nielsen, MD, PhD

  Professor
  Department of Pathology and Laboratory Medicine, University of British Columbia
  Vancouver, British Columbia, Canada
• MT

  Ming Tsao, MD, FRCPC

  Princess Margaret Cancer Centre
  Toronto, Ontario, Canada
• TC

  Tricia Cottrell, MD

  Canadian Cancer Trials Group
  Kingston, Ontario, Canada
• JS

  Joana Sederias, n/a

  Canadian Cancer Trials Group
  Kingston, Ontario, Canada
• SZ

  Siwei Zhang, n/a

  Canadian Cancer Trials Group
  Kingston, Ontario, Canada
• WT

  Wei Tu, n/a

  Canadian Cancer Trials Group
  Kingston, Ontario, Canada
• JD

  Janet Dancey, MD

  Canadian Cancer Trials Group
  Kingston, Ontario, Canada